NasdaqGS - Nasdaq Real Time Price USD

Shattuck Labs, Inc. (STTK)

10.13

+0.11

(+1.10%)

At close: April 18 at 4:00 PM EDT

Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),

Key Insights Significantly high institutional ownership implies Shattuck Labs' stock price is sensitive to their...

Simply Wall St. yesterday

STTK
+1.10%
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade – AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients

GlobeNewswire 9 days ago

STTK
+1.10%
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 23rd Annual Needham Virtual Healthcare Conference being held virtually from April 8-11, 2024. Presentation DetailsConference: 23

GlobeNewswire 18 days ago

STTK
+1.10%
Shattuck Labs Full Year 2023 Earnings: Beats Expectations

Shattuck Labs ( NASDAQ:STTK ) Full Year 2023 Results Key Financial Results Net loss: US$87.3m (loss narrowed by 14...

Simply Wall St. last month

STTK
+1.10%
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful execu

GlobeNewswire last month

STTK
+1.10%
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting – - Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m

GlobeNewswire last month

STTK
+1.10%
Shattuck Labs Announces Participation in Upcoming March Conferences

AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024. Presentation DetailsConference: TD Cowen 44th Annual Health Care ConferenceFormat: Pan

GlobeNewswire last month

STTK
+1.10%
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.

PR Newswire 2 months ago

STTK
+1.10%
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to generate novel bifunctional fusion proteins targeting certain pathways in autoimmune and in

GlobeNewswire 2 months ago

STTK
+1.10%
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024. “In 2023, we delivered key safety and efficacy data across our clinical development program for

GlobeNewswire 3 months ago

STTK
+1.10%
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco

GlobeNewswire 3 months ago

STTK
+1.10%
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

AUSTIN, TX and DURHAM, NC, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the pricing of a registered offering of 4,651,163 shares of common stock, par value $0.0001 (the “common stock”), at a price of $6.45 per share, which is pr

GlobeNewswire 3 months ago

STTK
+1.10%
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Shattuck Labs...

Simply Wall St. 3 months ago

STTK
+1.10%
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% – – Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment – – SL-172154 demonstrated an acceptable

GlobeNewswire 4 months ago

STTK
+1.10%
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call on initial data from its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and review data from the poster presentation featured a

GlobeNewswire 4 months ago

STTK
+1.10%
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 6th Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023. Presentation DetailsConference: 6th Annual Evercor

GlobeNewswire 5 months ago

STTK
+1.10%
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript

Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded. I will now turn the call over […]

Insider Monkey 5 months ago

STTK
+1.10%
Institutions profited after Shattuck Labs, Inc.'s (NASDAQ:STTK) market cap rose US$7.6m last week but individual investors profited the most

Key Insights Shattuck Labs' significant individual investors ownership suggests that the key decisions are influenced...

Simply Wall St. 5 months ago

STTK
+1.10%
Q3 2023 Shattuck Labs Inc Earnings Call

Q3 2023 Shattuck Labs Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

STTK
+1.10%
Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates

Key Clinical Progress and Financial Metrics Revealed

GuruFocus.com 5 months ago

STTK
+1.10%

Performance Overview

Return	STTK	S&P 500
YTD	+42.08%	+5.06%
1-Year	+251.74%	+20.71%
3-Year	-66.24%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Shattuck Labs, Inc. (STTK)

Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Shattuck Labs Full Year 2023 Earnings: Beats Expectations

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming March Conferences

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript

Institutions profited after Shattuck Labs, Inc.'s (NASDAQ:STTK) market cap rose US$7.6m last week but individual investors profited the most

Q3 2023 Shattuck Labs Inc Earnings Call

Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates

Performance Overview